Lexicon Pharmaceuticals has reported positive results from a clinical trial and mechanistic study of a solid oral dose formulation of LX4211 as a treatment for type II diabetes patients.
The clinical trial was designed to compare a the solid oral dose formulation of LX4211 to the liquid dose formulation.
The results showed that 300mg solid oral tablet dose of LX4211, administered as two 150mg tablets, significantly increased total Glucagon-like peptide(GLP)-1, active GLP-1 and Peptide YY, important mediators of glyceamic and appetite control, as well as other metabolic parameters.
Single doses of LX4211 resulted in rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG).
Pharmacokinetic and pharmacodynamic data from the study revealed that the solid oral formulation was as effective, if not better, as the liquid formulation on the key parameters of hormonal release, PPG and FPG.
The trial used a randomised, triple-cross over design in which 12 patients with type II diabetes were treated with 300mg of LX4211 in different dose forms.
LX4211 is an orally-delivered small molecule, that works by inhibiting sodium-glucose co-transporter type 1 and sodium-glucose co-transporter type 2.